Journal Article

Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment

Samra, Monica, Francis, Darrel P., Ruschitzka, Frank, Ziff, Oliver J., Bromage, Daniel I., Kotecha, Dipak, Howard, James P.

2020

Overview

Background Beta-blockers are widely used for many cardiovascular conditions; however, their efficacy in contemporary clinical practice remains uncertain. Methods We performed a prospectively designed, umbrella review of meta-analyses of randomised controlled trials (RCTs) investigating the evidence of beta-blockers in the contemporary management of coronary artery disease (CAD), heart failure (HF), patients undergoing surgery or hypertension (registration: PROSPERO CRD42016038375). We searched MEDLINE, EMBASE and the Cochrane Library from inception until December 2018. Outcomes were analysed as beta-blockers versus control for all-cause mortality, myocardial infarction (MI), incident HF or stroke. Two independent investigators abstracted the data, assessed the quality of the evidence and rated the certainty of evidence. Results We identified 98 meta-analyses, including 284 unique RCTs and 1,617,523 patient-years of follow-up. In CAD, 12 meta-analyses (93 RCTs, 103,481 patients) showed that beta-blockers reduced mortality in analyses before routine reperfusion, but there was a lack of benefit in contemporary studies where ≥ 50% of patients received thrombolytics or intervention. Beta-blockers reduced incident MI at the expense of increased HF. In HF with reduced ejection fraction, 34 meta-analyses (66 RCTs, 35,383 patients) demonstrated a reduction in mortality and HF hospitalisation with beta-blockers in sinus rhythm, but not in atrial fibrillation. In patients undergoing surgery, 23 meta-analyses (89 RCTs, 19,211 patients) showed no effect of beta-blockers on mortality for cardiac surgery, but increased mortality in non-cardiac surgery. In non-cardiac surgery, beta-blockers reduced MI after surgery but increased the risk of stroke. In hypertension, 27 meta-analyses (36 RCTs, 260,549 patients) identified no benefit versus placebo, but beta-blockers were inferior to other agents for preventing mortality and stroke. Conclusions Beta-blockers substantially reduce mortality in HF patients in sinus rhythm, but for other conditions, clinicians need to weigh up both benefit and potential risk.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adrenergic beta-Antagonists - pharmacology / Adrenergic beta-Antagonists - therapeutic use / Analysis / Atrial fibrillation / Beta blockers / Bias / Biomedicine / Cardiac arrhythmia / Cardiovascular disease / Cardiovascular Diseases - drug therapy / Cerebral infarction / Clinical trials / Confidence intervals / Congestive heart failure / Coronary artery / Coronary artery disease / Coronary vessels / Ejection fraction / Evidence-based medicine / Fibrillation / Health aspects / Health risks / Heart attack / Heart attacks / Heart failure / Heart surgery / Humans / Hypertension / Medicine / Medicine & Public Health / Meta-analysis / Mortality / Myocardial infarction / Patients / Perioperative / Prevention / Prospective Studies / Quality / Quality assessment / Reperfusion / Research Article / Rhythm / Sinuses / Stroke / Surgery / Systematic review